• NGLY1 in The New Yorker!

    Open science and social media were key in the discovery and growth of the NGLY1 rare disease community. Article by Seth Mnookin.

  • NGLY1 Deficiency Research

    In June 2012, the Freeze Lab pioneered research into the clinical treatment of the rare disorder, N-glycanase deficiency.

  • NGLY1 Families Connect

    On February 28, 2014, researchers and 5 NGLY1 families from across the world met for the first ever symposium on N-glycanase deficiency.

Showing posts with label definition. Show all posts
Showing posts with label definition. Show all posts

Monday, July 14, 2014

What is a "Natural History of Disease"?

The NIH Campus in Bethesda, Maryland, USA.
The National Institutes of Health (NIH) is currently enrolling N-glycanase (NGLY1) deficiency patients into a study of the natural history of the disease.

The natural history of disease refers to a description of the uninterrupted progression of a disease in an individual until recovery or death.

Knowledge of the natural history of disease ranks alongside causal understanding in importance for disease prevention and control.

Natural history studies and registries also play a critical role in the drug discovery and development process.

Standardized natural history registries, tied to tissue banking, facilitate the generation of research leads, and accelerate studies examining associations between phenotype (disease-related physical and mental characteristics) and genotype.

Patient registries represent one of the best resources to collect prevalence, demographic, natural history, and comparative effectiveness data on rare diseases.

Currently, very few rare disease patient registries exist and where they do, they are often limited in their usefulness.

The NIH, FDA, and NORD are currently in the process of building a rare disease patient registry program to ensure rare disease patients have adequate natural history information in order to spur drug discovery and development.